2. Anti-infection Cell Cycle/DNA Damage
  3. CMV HSV Antibiotic Nucleoside Antimetabolite/Analog
  4. Ganciclovir

Ganciclovir  (Synonyms: BW 759; 2'-Nor-2'-deoxyguanosine)

Cat. No.: HY-13637 Purity: 99.89%
COA
SDS
Handling Instructions Technical Support

Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain.

For research use only. We do not sell to patients.

CAS No. : 82410-32-0

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
100 mg In-stock
1 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 27 publication(s) in Google Scholar

Other Forms of Ganciclovir:

Ganciclovir Related Antibodies

Top Publications Citing Use of Products

    Ganciclovir purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2023 Nov 27;15(12):2680.

    GCV (1-30 μM) exhibited a dose-dependent decrease in newly synthesized DNA due to its inhibitory impact on the viral polymerase processing activity.

    Ganciclovir purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2022 Jul 20;20(1):340.  [Abstract]

    Long-term GCV (50 mg/kg, ip)-trigged nanoparticle-based therapy in ovarian cancer model.

    Ganciclovir purchased from MedChemExpress. Usage Cited in: Sci Data. 2022 Oct 8;9(1):610.  [Abstract]

    Exemplary overviews of one screening plate for each virus screen. Individual images of each well were stitched yielding the overviews. First two columns of each plate contained DMSO control solvent, the following 20 columns PCL compounds, and the last two columns the positive controls (BafA1 for RV and IAV, and GCV (25 μM) for HSV-1). Scale bar represents 10 mm.

    Ganciclovir purchased from MedChemExpress. Usage Cited in: Cell. 2020 Nov 25;183(5):1402-1419.e18.  [Abstract]

    In vivo studies of miR-124-HSV-tk-GFP teratomas in the presence of GCV administration (80mg/kg/d, 10 weeks) using both intratumoral (IT) and intratumoral and intraperitoneal injection methods. A heatmap showing cell type fraction log fold-change for each teratoma replicate compared to a control miR-124-HSV-tk-GFP teratoma in the absence of GCV. Z-scores for each cell type fraction change are plotted as well, with standard deviations calculated using a pooled variance.

    Ganciclovir purchased from MedChemExpress. Usage Cited in: Cells. 2019 Dec 20;9(1):31.  [Abstract]

    Antiviral effects of eltrombopag in combination with Ganciclovir (0.61-10000 nM). Effects of equimolar drug concentrations on HCMV LA expression in HCMV Hi91 (MOI 0.02) HFFs 120 h post infection. * p < 0.05 compared to either single treatment.

    Ganciclovir purchased from MedChemExpress. Usage Cited in: Eur J Pharm Sci. 2019 Jan 15:127:29-37.  [Abstract]

    Viral reporter GFP expression after inoculation and compound treatment. Infected cells treated with DMSO control, BIO, Ganciclovir (GCV) or Letermovir (LTR)

    View All HSV Isoform Specific Products:

    View All Isoforms
    HSV-1 HSV-2 HSV

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain[1][2][3].

    IC50 & Target[1][2][3]

    CMV

     

    HSV-1

     

    HSV-2

     

    FHV-1

    5.2 μM (IC50)

    Cellular Effect
    Cell Line Type Value Description References
    BC-3 IC50
    70 μM
    Compound: GCV
    Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay
    Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay
    		[PMID: 17402726]
    BJ EC50
    3 μM
    Compound: GCV
    Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days
    Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days
    		[PMID: 18458124]
    BSC-1 IC50
    3 μM
    Compound: Ganciclovir
    Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells
    Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells
    		[PMID: 2913300]
    BSC-1 IC50
    3.5 μM
    Compound: 1
    In vitro antiviral activity against HSV-1 virus in BSC-1 (monkey kidney) cells.
    In vitro antiviral activity against HSV-1 virus in BSC-1 (monkey kidney) cells.
    		[PMID: 9057865]
    BSC-1 IC50
    3.5 μM
    Compound: GCV (ganciclovir) (table-1)
    Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay
    Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay
    		[PMID: 15509174]
    BSC-1 IC50
    3.5 μM
    Compound: GCV (ganciclovir) (table-1)
    Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay
    Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay
    		[PMID: 15509175]
    BSC-1 IC50
    3.5 μM
    Compound: GCV (table-1)
    Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay
    Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay
    		[PMID: 15509176]
    BSC-1 IC50
    3.5 μM
    Compound: Ganciclovir
    Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells
    Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells
    		[PMID: 10882370]
    BSC-1 IC50
    3.5 μM
    Compound: Ganciclovir
    ELISA assay was performed using BSC-1 cells to determine activity against HSV-1
    ELISA assay was performed using BSC-1 cells to determine activity against HSV-1
    		[PMID: 10882372]
    BSC-1 IC50
    > 100 μM
    Compound: Ganciclovir
    Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells).
    Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells).
    		[PMID: 2175356]
    BSC-1 IC50
    > 100 μM
    Compound: Ganciclovir (DHPG)
    Cytotoxicity against Monkey kidney cells(BSC-1 cells)
    Cytotoxicity against Monkey kidney cells(BSC-1 cells)
    		[PMID: 2500527]
    BSC-1 IC50
    > 100 μM
    Compound: ganciclovir
    The compound was tested for cytotoxicity against BSC1 cell
    The compound was tested for cytotoxicity against BSC1 cell
    		[PMID: 2840500]
    Bone marrow cell CC50
    30 μM
    Compound: ganciclovir
    Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days
    Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days
    		[PMID: 17329103]
    CCRF-CEM CC50
    5 μM
    Compound: ganciclovir
    Cytotoxicity against CEM cells
    Cytotoxicity against CEM cells
    		[PMID: 15615545]
    CCRF-CEM CC50
    > 100 μM
    Compound: 1
    Cytostatic activity human CEM cells assessed as reduction in cell viability after 72 hrs by cell counting method
    Cytostatic activity human CEM cells assessed as reduction in cell viability after 72 hrs by cell counting method
    		[PMID: 28829913]
    CCRF-CEM CC50
    > 200 μM
    Compound: Ganciclovir
    Compound concentration required to reduce viability of CEM cells
    Compound concentration required to reduce viability of CEM cells
    		[PMID: 14643328]
    CCRF-CEM EC50
    > 200 μM
    Compound: Ganciclovir
    Compound was tested for anti-viral activity against HIV-1 in CEM cells
    Compound was tested for anti-viral activity against HIV-1 in CEM cells
    		[PMID: 14643328]
    CCRF-CEM EC50
    > 200 μM
    Compound: Ganciclovir
    Compound was tested for anti-viral activity against HIV-2 in CEM cells
    Compound was tested for anti-viral activity against HIV-2 in CEM cells
    		[PMID: 14643328]
    CCRF-CEM EC50
    > 50 μM
    Compound: Gancyclovir
    Antiviral activity against HIV1 IIIB in CEM cells
    Antiviral activity against HIV1 IIIB in CEM cells
    		[PMID: 16392791]
    CCRF-CEM EC50
    > 50 μM
    Compound: Gancyclovir
    Antiviral activity against HIV2 ROD in CEM cells
    Antiviral activity against HIV2 ROD in CEM cells
    		[PMID: 16392791]
    CCRF-CEM IC50
    > 390 μM
    Compound: Ganciclovir
    In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity
    In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity
    		[PMID: 11814776]
    CCRF-HSB-2 IC50
    17 μg/mL
    Compound: DHPG
    Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.
    Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.
    		[PMID: 9216836]
    CFU-GM IC50
    19 μM
    Compound: Ganciclovir
    In vitro toxicity against colony forming unit granulocyte macrophage (CFU-GM)
    In vitro toxicity against colony forming unit granulocyte macrophage (CFU-GM)
    		[PMID: 8176714]
    DG-75 IC50
    > 100 μM
    Compound: GCV
    Cytotoxicity against DG75 cells after 120 hrs by MTT assay
    Cytotoxicity against DG75 cells after 120 hrs by MTT assay
    		[PMID: 17402726]
    E6SM CC50
    > 100 μg/mL
    Compound: ganciclovir
    Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells
    Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells
    		[PMID: 8709116]
    E6SM EC50
    0.0012 μM
    Compound: Gancyclovir, DHPG
    Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines
    Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines
    		[PMID: 11495586]
    E6SM EC50
    0.0012 μM
    Compound: Gancyclovir, DHPG
    Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines
    Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines
    		[PMID: 11495586]
    E6SM EC50
    0.002 μg/mL
    Compound: ganciclovir
    Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17518459]
    E6SM EC50
    0.003 μg/mL
    Compound: ganciclovir
    Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture
    Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture
    		[PMID: 15481985]
    E6SM EC50
    0.004 μg/mL
    Compound: ganciclovir
    Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture
    Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture
    		[PMID: 15481985]
    E6SM EC50
    0.007 μg/mL
    Compound: ganciclovir
    Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17518459]
    E6SM EC50
    0.019 μg/mL
    Compound: Ganciclovir
    Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    0.019 μg/mL
    Compound: Ganciclovir
    Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    0.019 μg/mL
    Compound: Ganciclovir
    Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    0.019 μg/mL
    Compound: Ganciclovir
    Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    0.019 μg/mL
    Compound: Ganciclovir
    Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    0.02 μg/mL
    Compound: ganciclovir
    Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17518459]
    E6SM EC50
    0.032 μg/mL
    Compound: Ganciclovir
    Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    0.7 μg/mL
    Compound: ganciclovir
    Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17518459]
    E6SM EC50
    2.4 μg/mL
    Compound: Ganciclovir
    Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    2.4 μg/mL
    Compound: ganciclovir
    Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture
    Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture
    		[PMID: 15481985]
    E6SM EC50
    > 100 μM
    Compound: Gancyclovir, DHPG
    Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines
    Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines
    		[PMID: 11495586]
    E6SM EC50
    > 100 μg/mL
    Compound: Ganciclovir
    Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    > 100 μg/mL
    Compound: Ganciclovir
    Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle
    Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle
    		[PMID: 12459010]
    E6SM EC50
    > 100 μg/mL
    Compound: ganciclovir
    Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture
    Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture
    		[PMID: 15481985]
    E6SM EC50
    > 100 μg/mL
    Compound: ganciclovir
    Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17518459]
    Fibroblast EC50
    0.04 μM
    Compound: 10
    Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 19397271]
    Fibroblast EC50
    1.2 μM
    Compound: 10
    Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay
    Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay
    		[PMID: 19397271]
    Fibroblast EC50
    5.5 μM
    Compound: 10
    Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay
    Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay
    		[PMID: 19397271]
    Fibroblast IC50
    0.05 μM
    Compound: 1 (BW-B759U, ganciclovir)
    Inhibition of growth of Epstein Barr virus(EBV) in human lung fibroblast cell line
    Inhibition of growth of Epstein Barr virus(EBV) in human lung fibroblast cell line
    		[PMID: 2826784]
    Fibroblast IC50
    156 μM
    Compound: GCV
    Inhibitory activity against human foreskin fibroblast cell proliferation
    Inhibitory activity against human foreskin fibroblast cell proliferation
    		[PMID: 11708924]
    Fibroblast IC50
    168 μM
    Compound: ganciclovir
    Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells
    Concentration of the drug required to reduce the proliferation of human foreskin fibroblast cells
    		[PMID: 8394933]
    Fibroblast IC50
    3.4 μM
    Compound: 1 (BW-B759U, ganciclovir)
    Inhibition of growth of human cytomegalovirus (HCMV) was determined by plaque reduction assay in human lung fibroblast cell line
    Inhibition of growth of human cytomegalovirus (HCMV) was determined by plaque reduction assay in human lung fibroblast cell line
    		[PMID: 2826784]
    Fibroblast IC50
    > 100 μM
    Compound: Ganciclovir (DHPG)
    Cytotoxicity against Normal human diploid cells (human foreskin fibroblasts cells)
    Cytotoxicity against Normal human diploid cells (human foreskin fibroblasts cells)
    		[PMID: 2500527]
    HEL CC50
    1077 μM
    Compound: Ganciclovir
    Cytotoxicity against HEL
    Cytotoxicity against HEL
    		[PMID: 20809641]
    HEL CC50
    122 μg/mL
    Compound: gancyclovir
    Cytotoxicity against HEL cells assessed as cell growth after 3 days
    Cytotoxicity against HEL cells assessed as cell growth after 3 days
    		[PMID: 17948980]
    HEL CC50
    130 μM
    Compound: Ganciclovir
    Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter
    Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter
    		[PMID: 22578783]
    HEL CC50
    130 μM
    Compound: Ganciclovir
    Cytostatic activity against human HEL cells assessed as reduction in cell growth measured after 24 hrs
    Cytostatic activity against human HEL cells assessed as reduction in cell growth measured after 24 hrs
    		[PMID: 38643669]
    HEL CC50
    134 μM
    Compound: GCV, ganciclovir
    Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days
    Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days
    		[PMID: 19226140]
    HEL CC50
    146 μg/mL
    Compound: ganciclovir
    Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days
    Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days
    		[PMID: 17869124]
    HEL CC50
    146 μg/mL
    Compound: ganciclovir
    Cytotoxicity against HEL cells assessed as reduction of growth after 3 days
    Cytotoxicity against HEL cells assessed as reduction of growth after 3 days
    		[PMID: 18835175]
    HEL CC50
    164 μM
    Compound: Ganciclovir
    Cytotoxicity against human HEL cells after 3 days
    Cytotoxicity against human HEL cells after 3 days
    		[PMID: 21128666]
    HEL CC50
    172 μM
    Compound: ganciclovir
    Cytotoxicity against HEL cells assessed as cell growth after 7 days
    Cytotoxicity against HEL cells assessed as cell growth after 7 days
    		[PMID: 17539622]
    HEL CC50
    172 μM
    Compound: ganciclovir
    Cytotoxicity against HEL cells assessed as reduction in cell growth
    Cytotoxicity against HEL cells assessed as reduction in cell growth
    		[PMID: 17961851]
    HEL CC50
    200 μM
    Compound: Ganciclovir
    Cytotoxicity against HEL
    Cytotoxicity against HEL
    		[PMID: 23743443]
    HEL CC50
    200 μg/mL
    Compound: 11) 2 (Ganciclovir GCV)
    Cytotoxicity (to reduce cell growth) against Cytomegalovirus in human embryonic lung (HEL) cells
    Cytotoxicity (to reduce cell growth) against Cytomegalovirus in human embryonic lung (HEL) cells
    		10.1016/S0960-894X(01)80538-2
    HEL CC50
    221 μM
    Compound: 1b, GCV
    Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days
    Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days
    		[PMID: 19339082]
    HEL CC50
    231 μM
    Compound: Ganciclovir
    Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay
    Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay
    		[PMID: 22858222]
    HEL CC50
    231.22 μM
    Compound: Ganciclovir
    Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis
    Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis
    		[PMID: 33479570]
    HEL CC50
    262 μM
    Compound: ganciclovir
    Cytotoxicity against human HEL cells assessed as reduction of cell growth
    Cytotoxicity against human HEL cells assessed as reduction of cell growth
    		[PMID: 17672445]
    HEL CC50
    273 μM
    Compound: 1
    Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method
    Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method
    		[PMID: 28829913]
    HEL CC50
    308 μM
    Compound: Ganciclovir
    Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method
    Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method
    		[PMID: 28757102]
    HEL CC50
    328.5 μM
    Compound: Ganciclovir
    Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days
    Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days
    		[PMID: 26291038]
    HEL CC50
    34 μg/mL
    Compound: ganciclovir
    Cytotoxicity against HEL cells
    Cytotoxicity against HEL cells
    		[PMID: 16480257]
    HEL CC50
    394 μM
    Compound: ganciclovir
    Inhibition of cell growth in HEL cells.
    Inhibition of cell growth in HEL cells.
    		[PMID: 10966745]
    HEL CC50
    400 μg/mL
    Compound: Ganciclovir
    Cytotoxicity against Cytomegalovirus infected HEL cells assessed as change in cell morphology
    Cytotoxicity against Cytomegalovirus infected HEL cells assessed as change in cell morphology
    		[PMID: 19324473]
    HEL CC50
    435 μM
    Compound: Ganciclovir
    Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter
    Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter
    		[PMID: 21565516]
    HEL CC50
    543 μM
    Compound: Ganciclovir
    Cytotoxicity against human HEL cells after 3 days by coulter counter
    Cytotoxicity against human HEL cells after 3 days by coulter counter
    		[PMID: 21745746]
    HEL CC50
    60.5 μg/mL
    Compound: Ganciclovir
    Cytotoxicity against HEL
    Cytotoxicity against HEL
    		10.1007/s00044-011-9776-0
    HEL CC50
    65.4 μg/mL
    Compound: GCV (Ganciclovir)
    Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells
    Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells
    		[PMID: 15658861]
    HEL CC50
    65.4 μg/mL
    Compound: GCV (Ganciclovir)
    Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells
    Cytotoxic concentration to reduce the 50% cell growth of human embryonic lung cells
    		[PMID: 15658861]
    HEL CC50
    80 μg/mL
    Compound: Ganciclovir
    Cytotoxicity against Cytomegalovirus infected HEL cells assessed as reduction in cell growth
    Cytotoxicity against Cytomegalovirus infected HEL cells assessed as reduction in cell growth
    		[PMID: 19324473]
    HEL CC50
    87 μg/mL
    Compound: Ganciclovir
    Cytotoxicity against human HEL cells assessed as reduction of cell growth
    Cytotoxicity against human HEL cells assessed as reduction of cell growth
    		[PMID: 17583388]
    HEL CC50
    > 100 μM
    Compound: Ganciclovir
    Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method
    Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method
    		[PMID: 20034711]
    HEL CC50
    > 100 μM
    Compound: Ganciclovir
    Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method
    Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method
    		[PMID: 20034711]
    HEL CC50
    > 100 μM
    Compound: Ganciclovir
    Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method
    Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method
    		[PMID: 20034711]
    HEL CC50
    > 100 μM
    Compound: Ganciclovir
    Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method
    Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method
    		[PMID: 20034711]
    HEL CC50
    > 100 μM
    Compound: Ganciclovir
    Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method
    Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method
    		[PMID: 20034711]
    HEL CC50
    > 100 μM
    Compound: Gancyclovir
    Cytotoxicity against HEL cells
    Cytotoxicity against HEL cells
    		[PMID: 17181162]
    HEL CC50
    > 150 μM
    Compound: DHPG(ganciclovir)
    Cytotoxic concentration required to reduce HEL cell growth by 50%
    Cytotoxic concentration required to reduce HEL cell growth by 50%
    		[PMID: 15081019]
    HEL CC50
    > 150 μM
    Compound: Ganciclovir
    Concentration required against HEL cell proliferation
    Concentration required against HEL cell proliferation
    		[PMID: 14643358]
    HEL CC50
    > 150 μM
    Compound: Ganciclovir
    Cytostatic concentration required to inhibit HEL cell proliferation measured at day 4
    Cytostatic concentration required to inhibit HEL cell proliferation measured at day 4
    		[PMID: 15027877]
    HEL CC50
    > 150 μM
    Compound: Ganciclovir
    Cytotoxic concentration required to reduce HEL cell growth
    Cytotoxic concentration required to reduce HEL cell growth
    		[PMID: 15801851]
    HEL CC50
    > 150 μM
    Compound: ganciclovir
    Cytotoxic concentration required to reduce HEL cell growth by 50%
    Cytotoxic concentration required to reduce HEL cell growth by 50%
    		[PMID: 15481985]
    HEL CC50
    > 197 μM
    Compound: GCV
    Cytotoxic activity against cultured human embryonic lung (HEL) cells
    Cytotoxic activity against cultured human embryonic lung (HEL) cells
    		[PMID: 16392824]
    HEL CC50
    > 200 μM
    Compound: GCV
    Cytotoxicity against HEL cells after 3 days
    Cytotoxicity against HEL cells after 3 days
    		[PMID: 17622128]
    HEL CC50
    > 200 μg/mL
    Compound: GCV
    Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.
    Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.
    		[PMID: 7877148]
    HEL CC50
    > 250 μM
    Compound: Ganciclovir
    Cytotoxicity against HEL cells after 3 days by coulter counter analysis
    Cytotoxicity against HEL cells after 3 days by coulter counter analysis
    		[PMID: 21232828]
    HEL CC50
    > 300 μM
    Compound: Ganciclovir
    Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method
    Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method
    		[PMID: 33894564]
    HEL CC50
    > 319 μM
    Compound: Ganciclovir
    Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method
    Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method
    		[PMID: 29670705]
    HEL CC50
    > 350 μM
    Compound: Ganciclovir
    Cytotoxicity against human HEL cells after 3 days by Coulter counting method
    Cytotoxicity against human HEL cells after 3 days by Coulter counting method
    		[PMID: 23911854]
    HEL CC50
    > 350 μM
    Compound: Ganciclovir
    Cytotoxicity against HEL cells infected with Cytomegalovirus assessed as growth inhibition
    Cytotoxicity against HEL cells infected with Cytomegalovirus assessed as growth inhibition
    		[PMID: 27750154]
    HEL CC50
    > 350 μM
    Compound: Ganciclovir
    Cytostatic activity against HEL cells after 3 days by Coulter counting method
    Cytostatic activity against HEL cells after 3 days by Coulter counting method
    		[PMID: 29407990]
    HEL CC50
    > 391 μM
    Compound: Ganciclovir
    Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method
    Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method
    		[PMID: 28682067]
    HEL CC50
    > 391 μM
    Compound: Ganciclovir
    Cytostatic activity against HEL cells after 3 days by Coulter counting method
    Cytostatic activity against HEL cells after 3 days by Coulter counting method
    		[PMID: 29550734]
    HEL CC50
    > 394 μM
    Compound: Ganciclovir
    Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method
    Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method
    		[PMID: 32676147]
    HEL CC50
    > 400 μM
    Compound: Ganciclovir
    Compound concentration required to reduce viability of HEL cells
    Compound concentration required to reduce viability of HEL cells
    		[PMID: 14643328]
    HEL CC50
    > 50 μg/mL
    Compound: Ganciclovir
    The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells
    The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells
    		[PMID: 10197958]
    HEL CC50
    > 50 μg/mL
    Compound: Ganciclovir
    Cytotoxic concentration reducing HEL cell growth by 50%.
    Cytotoxic concentration reducing HEL cell growth by 50%.
    		[PMID: 12217359]
    HEL CC50
    >= 319 μM
    Compound: GCV
    Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method
    Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method
    		[PMID: 26443550]
    HEL EC50
    0.00038 μg/mL
    Compound: ganciclovir
    Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    0.00056 μg/mL
    Compound: gancyclovir
    Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    0.0014 μg/mL
    Compound: ganciclovir
    Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HSV2 Lyons in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    0.0014 μg/mL
    Compound: gancyclovir
    Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HSV2 Lyons in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    0.0036 μg/mL
    Compound: gancyclovir
    Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    0.0096 μg/mL
    Compound: ganciclovir
    Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HSV2 G in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    0.01 μM
    Compound: Ganciclovir
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    0.01 μM
    Compound: ganciclovir
    Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
    Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
    		[PMID: 23795238]
    HEL EC50
    0.01 μM
    Compound: ganciclovir
    Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
    Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
    		[PMID: 23795238]
    HEL EC50
    0.013 μM
    Compound: Ganciclovir
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    HEL EC50
    0.015 μM
    Compound: Ganciclovir
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    HEL EC50
    0.019 μM
    Compound: Gancyclovir
    Antiviral activity against HSV1 KOS in HEL cells
    Antiviral activity against HSV1 KOS in HEL cells
    		[PMID: 17181162]
    HEL EC50
    0.02 μM
    Compound: GCV
    Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    0.02 μM
    Compound: Ganciclovir
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HEL EC50
    0.02 μM
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    HEL EC50
    0.027 μM
    Compound: Ganciclovir
    Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    0.027 μM
    Compound: Ganciclovir
    Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay
    Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay
    		[PMID: 22858222]
    HEL EC50
    0.029 μM
    Compound: Ganciclovir
    Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay
    Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay
    		[PMID: 22858222]
    HEL EC50
    0.03 μM
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    		[PMID: 20034711]
    HEL EC50
    0.03 μM
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    		[PMID: 20034711]
    HEL EC50
    0.03 μM
    Compound: Ganciclovir
    Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    		[PMID: 20034711]
    HEL EC50
    0.03 μM
    Compound: Ganciclovir
    Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    0.03 μM
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    		[PMID: 21696963]
    HEL EC50
    0.03 μM
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    		[PMID: 21696963]
    HEL EC50
    0.03 μM
    Compound: Ganciclovir
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HEL EC50
    0.03 μM
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HEL EC50
    0.03 μM
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HEL EC50
    0.03 μM
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    HEL EC50
    0.03 μM
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation
    		[PMID: 27639368]
    HEL EC50
    0.032 μM
    Compound: Gancyclovir
    Antiviral activity against HSV2 in HEL cells
    Antiviral activity against HSV2 in HEL cells
    		[PMID: 17181162]
    HEL EC50
    0.03 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    0.03 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    0.04 μM
    Compound: Ganciclovir
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    0.05 μM
    Compound: Ganciclovir
    Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    		[PMID: 21128666]
    HEL EC50
    0.05 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    0.06 μM
    Compound: Ganciclovir
    Compound was tested for anti-viral activity against HSV-1(G) in HEL cells
    Compound was tested for anti-viral activity against HSV-1(G) in HEL cells
    		[PMID: 14643328]
    HEL EC50
    0.06 μM
    Compound: Gancyclovir
    Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells
    Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells
    		[PMID: 15658858]
    HEL EC50
    0.06 μM
    Compound: Gancyclovir
    Antiviral activity against HSV1 KOS in HEL cells
    Antiviral activity against HSV1 KOS in HEL cells
    		[PMID: 16392791]
    HEL EC50
    0.06 μM
    Compound: Gancyclovir
    Antiviral activity against HSV2 G in HEL cells
    Antiviral activity against HSV2 G in HEL cells
    		[PMID: 16392791]
    HEL EC50
    0.06 μg/mL
    Compound: Ganciclovir
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    0.06 μg/mL
    Compound: Ganciclovir
    Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    0.07 μM
    Compound: Ganciclovir
    Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HEL EC50
    0.07 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    0.08 μM
    Compound: Ganciclovir
    Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    0.08 μM
    Compound: Ganciclovir
    Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    0.08 μM
    Compound: Ganciclovir
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    		[PMID: 21128666]
    HEL EC50
    0.08 μg/mL
    Compound: ganciclovir
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    0.08 μg/mL
    Compound: ganciclovir
    Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    0.09 μM
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
    Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
    		[PMID: 27639368]
    HEL EC50
    0.09 μM
    Compound: Ganciclovir
    Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HEL EC50
    0.1 μM
    Compound: Ganciclovir
    Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    0.2 μM
    Compound: GCV
    Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    0.25 μM
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus AD169 infected in HEL cells
    Antiviral activity against Cytomegalovirus AD169 infected in HEL cells
    		[PMID: 27128178]
    HEL EC50
    0.37 μg/mL
    Compound: Ganciclovir
    Effective concentration against AD-169 strain of CMV virus expressed in HEL cells
    Effective concentration against AD-169 strain of CMV virus expressed in HEL cells
    		[PMID: 15689173]
    HEL EC50
    0.37 μg/mL
    Compound: Ganciclovir
    Effective concentration against Davis strain of CMV virus expressed in HEL cells
    Effective concentration against Davis strain of CMV virus expressed in HEL cells
    		[PMID: 15689173]
    HEL EC50
    0.38 μM
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation
    		[PMID: 23911856]
    HEL EC50
    0.4 μM
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus Davis 07/1 infected in HEL cells
    Antiviral activity against Cytomegalovirus Davis 07/1 infected in HEL cells
    		[PMID: 27128178]
    HEL EC50
    0.48 μM
    Compound: Gancyclovir
    Antiviral activity against HSV1 KOS in HEL cells
    Antiviral activity against HSV1 KOS in HEL cells
    		[PMID: 17181162]
    HEL EC50
    0.5 μM
    Compound: Ganciclovir
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    HEL EC50
    0.5 μM
    Compound: ganciclovir
    Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture
    Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture
    		[PMID: 15481985]
    HEL EC50
    0.51 μg/mL
    Compound: ganciclovir
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days
    		[PMID: 17869124]
    HEL EC50
    0.51 μg/mL
    Compound: ganciclovir
    Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity
    Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as inhibition of viral cytopathicity
    		[PMID: 18835175]
    HEL EC50
    0.54 μg/mL
    Compound: GCV
    Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    0.59 μM
    Compound: 1b, GCV
    Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
    Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
    		[PMID: 19339082]
    HEL EC50
    0.64 μg/mL
    Compound: Ganciclovir
    Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against human cytomegalovirus AD169 infected HEL cells assessed as reduction in virus plaque formation
    		[PMID: 17583388]
    HEL EC50
    0.66 μM
    Compound: GCV, ganciclovir
    Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    0.69 μM
    Compound: GCV, ganciclovir
    Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    0.7 μM
    Compound: GCV, ganciclovir
    Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    0.8 μM
    Compound: DHPG(ganciclovir)
    Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures
    Effective concentration against human cytomegalovirus Davies strain in HEL cell cultures
    		[PMID: 15081019]
    HEL EC50
    0.8 μM
    Compound: Ganciclovir
    Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    		[PMID: 21696963]
    HEL EC50
    0.8 μg/mL
    Compound: ganciclovir
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days
    		[PMID: 17869124]
    HEL EC50
    0.8 μg/mL
    Compound: ganciclovir
    Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity
    Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as inhibition of viral cytopathicity
    		[PMID: 18835175]
    HEL EC50
    0.9 μM
    Compound: DHPG(ganciclovir)
    Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures
    Effective concentration against human cytomegalovirus AD-169 strain in HEL cell cultures
    		[PMID: 15081019]
    HEL EC50
    0.9 μM
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    HEL EC50
    0.91 μg/mL
    Compound: ganciclovir
    Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against ACV-resistant TK- HSV1 KOS in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    0.9 μg/mL
    Compound: gancyclovir
    Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against acyclovir-resistant HSV1 KOS TK- in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    1 μM
    Compound: ganciclovir
    Antiviral activity against ACV-resistant TK-deficient HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
    Antiviral activity against ACV-resistant TK-deficient HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
    		[PMID: 23795238]
    HEL EC50
    1.1 μM
    Compound: 1b, GCV
    Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days
    Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days
    		[PMID: 19339082]
    HEL EC50
    1.2 μM
    Compound: GCV, ganciclovir
    Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    1.29 μg/mL
    Compound: gancyclovir
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    1.3 μM
    Compound: ganciclovir
    Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days
    Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days
    		[PMID: 17539622]
    HEL EC50
    1.3 μM
    Compound: ganciclovir
    Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
    Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
    		[PMID: 17961851]
    HEL EC50
    1.4 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation
    		[PMID: 19324473]
    HEL EC50
    1.5 μM
    Compound: Ganciclovir
    Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
    Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
    		[PMID: 15801851]
    HEL EC50
    1.5 μM
    Compound: Ganciclovir
    Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
    Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
    		[PMID: 15801851]
    HEL EC50
    1.5 μM
    Compound: ganciclovir
    Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture
    Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture
    		[PMID: 15481985]
    HEL EC50
    1.5 μg/mL
    Compound: GCV
    Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    1.5 μg/mL
    Compound: ganciclovir
    Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HCMV AD169 in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    1.5 μg/mL
    Compound: ganciclovir
    Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against HCMV Davis in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 17298047]
    HEL EC50
    1.65 μM
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days
    Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days
    		[PMID: 22459876]
    HEL EC50
    1.65 μM
    Compound: Ganciclovir
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days
    		[PMID: 22459876]
    HEL EC50
    1.68 μg/mL
    Compound: gancyclovir
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 17948980]
    HEL EC50
    1.79 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation
    Antiviral activity against Human herpesvirus 5 Davis infected human HEL cells assessed as reduction in the virus plaque formation
    		10.1007/s00044-011-9776-0
    HEL EC50
    1.7 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation
    		[PMID: 19324473]
    HEL EC50
    1.9 μg/mL
    Compound: Ganciclovir
    Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against human cytomegalovirus Davis infected HEL cells assessed as reduction in virus plaque formation
    		[PMID: 17583388]
    HEL EC50
    100 μM
    Compound: Ganciclovir
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HEL EC50
    100 μM
    Compound: Ganciclovir
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation
    		[PMID: 27639368]
    HEL EC50
    100 μM
    Compound: ganciclovir
    Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
    Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity
    		[PMID: 23795238]
    HEL EC50
    11.8 μM
    Compound: Gancyclovir, DHPG
    Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in Davis-169 strain HEL cell lines
    Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in Davis-169 strain HEL cell lines
    		[PMID: 11495586]
    HEL EC50
    12.6 μM
    Compound: 1b, GCV
    Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
    Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
    		[PMID: 19339082]
    HEL EC50
    13 μM
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days
    Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days
    		[PMID: 32676147]
    HEL EC50
    13.9 μM
    Compound: GCV
    Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation
    Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation
    		[PMID: 26443550]
    HEL EC50
    14.7 μM
    Compound: Ganciclovir
    Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay
    Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay
    		[PMID: 22858222]
    HEL EC50
    15.7 μM
    Compound: Ganciclovir
    Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    15 μg/mL
    Compound: Ganciclovir
    Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against thymidine kinase deficient Varicella Zoster Virus 07/1 infected in HEL cells assessed as reduction in virus plaque formation
    		[PMID: 19324473]
    HEL EC50
    1 μg/mL
    Compound: Ganciclovir
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    1 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against Varicella Zoster Virus OKA infected in HEL cells assessed as reduction in virus plaque formation
    		[PMID: 19324473]
    HEL EC50
    2 μM
    Compound: GCV, ganciclovir
    Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection
    Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection
    		[PMID: 19226140]
    HEL EC50
    2.1 μM
    Compound: Ganciclovir
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation
    		[PMID: 27639368]
    HEL EC50
    2.3 μM
    Compound: GCV
    Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days
    Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days
    		[PMID: 17622128]
    HEL EC50
    2.5 μM
    Compound: 1b, GCV
    Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
    Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
    		[PMID: 19339082]
    HEL EC50
    2.5 μM
    Compound: 1b, GCV
    Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
    Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
    		[PMID: 19339082]
    HEL EC50
    2.6 μM
    Compound: GCV, ganciclovir
    Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    2.6 μM
    Compound: ganciclovir
    Antiviral activity against CMV Davis in human HEL cells after 7 days
    Antiviral activity against CMV Davis in human HEL cells after 7 days
    		[PMID: 17672445]
    HEL EC50
    2.68 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation
    Antiviral activity against Human herpesvirus 5 strain AD169 infected human HEL cells assessed as reduction in the virus plaque formation
    		10.1007/s00044-011-9776-0
    HEL EC50
    2.7 μM
    Compound: Ganciclovir
    Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection
    Effective concentration required to inhibit HCMV AD169 strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection
    		[PMID: 15027877]
    HEL EC50
    2.75 μM
    Compound: ganciclovir
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation
    		[PMID: 17518459]
    HEL EC50
    2 μg/mL
    Compound: Ganciclovir
    Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    3 μM
    Compound: Ganciclovir
    Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    		[PMID: 21128666]
    HEL EC50
    3.1 μM
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation
    Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation
    		[PMID: 23911856]
    HEL EC50
    3.1 μM
    Compound: Ganciclovir
    Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation
    Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation
    		[PMID: 27639368]
    HEL EC50
    3.5 μM
    Compound: GCV, ganciclovir
    Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    3.6 μM
    Compound: GCV, ganciclovir
    Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection
    Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection
    		[PMID: 19226140]
    HEL EC50
    3.9 μM
    Compound: Ganciclovir
    Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection
    Effective concentration required to inhibit HCMV Davis strain-induced cytopathicity in human embryonic lung (HEL) fibroblast cell cultures at day 7 of postinfection
    		[PMID: 15027877]
    HEL EC50
    4 μM
    Compound: GCV, ganciclovir
    Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    4 μM
    Compound: Ganciclovir
    Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    HEL EC50
    4 μM
    Compound: Ganciclovir
    Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HEL EC50
    4.3 μM
    Compound: GCV, ganciclovir
    Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 19226140]
    HEL EC50
    4.44 μM
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days
    Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days
    		[PMID: 32676147]
    HEL EC50
    4.72 μM
    Compound: Ganciclovir
    Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy
    Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy
    		[PMID: 26291038]
    HEL EC50
    4.8 μM
    Compound: ganciclovir
    Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days
    Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days
    		[PMID: 17539622]
    HEL EC50
    4.8 μM
    Compound: ganciclovir
    Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
    Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
    		[PMID: 17961851]
    HEL EC50
    4.9 μg/mL
    Compound: GCV
    Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    5.1 μM
    Compound: GCV
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days
    		[PMID: 17622128]
    HEL EC50
    5.2 μM
    Compound: Ganciclovir
    Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    		[PMID: 21128666]
    HEL EC50
    5.9 μM
    Compound: Ganciclovir
    Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay
    Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay
    		[PMID: 22858222]
    HEL EC50
    5.98 μM
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation
    Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation
    		[PMID: 23811093]
    HEL EC50
    58 μg/mL
    Compound: Ganciclovir
    Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    6 μM
    Compound: Ganciclovir
    Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    6 μM
    Compound: Ganciclovir
    Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    6.12 μM
    Compound: Ganciclovir
    Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy
    Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy
    		[PMID: 26291038]
    HEL EC50
    6.2 μg/mL
    Compound: GCV
    Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    6.3 μM
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    HEL EC50
    6.3 μM
    Compound: ganciclovir
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation
    Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation
    		[PMID: 17518459]
    HEL EC50
    6.5 μM
    Compound: ganciclovir
    Antiviral activity against CMV AD169 in human HEL cells after 7 days
    Antiviral activity against CMV AD169 in human HEL cells after 7 days
    		[PMID: 17672445]
    HEL EC50
    6.54 μM
    Compound: Ganciclovir
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    6 μg/mL
    Compound: GCV
    Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    6 μg/mL
    Compound: ganciclovir
    Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    7.1 μM
    Compound: Ganciclovir
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity
    Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity
    		[PMID: 22578783]
    HEL EC50
    7.1 μM
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    HEL EC50
    7.5 μM
    Compound: Ganciclovir
    Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity
    Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity
    		[PMID: 22578783]
    HEL EC50
    7.6 μg/mL
    Compound: GCV
    Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    7.8 μM
    Compound: GCV
    Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation
    Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation
    		[PMID: 26443550]
    HEL EC50
    7.8 μM
    Compound: Gancyclovir, DHPG
    Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in AD-169 strain HEL cell lines
    Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in AD-169 strain HEL cell lines
    		[PMID: 11495586]
    HEL EC50
    7.87 μM
    Compound: Ganciclovir
    Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation
    Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation
    		[PMID: 23811093]
    HEL EC50
    8.2 μM
    Compound: Ganciclovir
    Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after
    Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after
    		[PMID: 23911854]
    HEL EC50
    8.7 μM
    Compound: GCV
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days
    Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days
    		[PMID: 17622128]
    HEL EC50
    9 μM
    Compound: GCV
    Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    9.1 μM
    Compound: Ganciclovir
    Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay
    Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay
    		[PMID: 22858222]
    HEL EC50
    9.1 μg/mL
    Compound: GCV
    Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    9.4 μg/mL
    Compound: GCV
    Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 18707089]
    HEL EC50
    > 100 μM
    Compound: GCV
    Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    > 100 μM
    Compound: GCV
    Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 19281225]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    		10.1007/s00044-009-9248-y
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay
    Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay
    		[PMID: 20034711]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay
    		[PMID: 20034711]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days
    		[PMID: 21128666]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 21232828]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
    		[PMID: 21696963]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
    		[PMID: 22459876]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect
    		[PMID: 23099097]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 23811093]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity
    		[PMID: 23911856]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as reduction of virus-induced cytopathogenicity
    		[PMID: 26001344]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HEL EC50
    > 100 μM
    Compound: Ganciclovir
    Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HEL EC50
    > 100 μM
    Compound: Gancyclovir
    Antiviral activity against vaccinia virus in HEL cells
    Antiviral activity against vaccinia virus in HEL cells
    		[PMID: 17181162]
    HEL EC50
    > 100 μM
    Compound: Gancyclovir
    Antiviral activity against vesicular somatitis virus in HEL cells
    Antiviral activity against vesicular somatitis virus in HEL cells
    		[PMID: 17181162]
    HEL EC50
    > 100 μg/mL
    Compound: Ganciclovir
    Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    > 100 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days
    		[PMID: 18851889]
    HEL EC50
    > 100 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    > 100 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days
    		[PMID: 20724039]
    HEL EC50
    > 100 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    > 100 μg/mL
    Compound: Ganciclovir
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay
    		[PMID: 20971531]
    HEL EC50
    > 100 μg/mL
    Compound: ganciclovir
    Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    > 100 μg/mL
    Compound: ganciclovir
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days
    		[PMID: 19419804]
    HEL EC50
    > 250 μM
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity
    Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection against virus-induced cytopathicity
    		[PMID: 21565516]
    HEL EC50
    >= 20 μM
    Compound: Ganciclovir
    Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
    		[PMID: 32214762]
    HEL EC50
    >= 93 μM
    Compound: Ganciclovir
    Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay
    Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay
    		[PMID: 22858222]
    HEL ED50
    0.016 μg/mL
    Compound: DHPG
    Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells.
    Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells.
    		[PMID: 9216836]
    HEL ED50
    0.039 μg/mL
    Compound: DHPG
    Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells.
    Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells.
    		[PMID: 9216836]
    HEL ED50
    0.21 μg/mL
    Compound: DHPG
    Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells.
    Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells.
    		[PMID: 9216836]
    HEL ED50
    0.21 μg/mL
    Compound: DHPG
    Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells.
    Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells.
    		[PMID: 9216836]
    HEL IC50
    0.02 μg/mL
    Compound: GCV
    Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.
    Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.
    		[PMID: 7877148]
    HEL IC50
    0.072 μg/mL
    Compound: GCV
    Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%
    Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%
    		[PMID: 7877148]
    HEL IC50
    0.1 μg/mL
    Compound: GCV
    Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.
    Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.
    		[PMID: 7877148]
    HEL IC50
    0.5 μM
    Compound: ganciclovir
    Inhibition of human CMV DNA synthesis in CMV-infected HEL cells.
    Inhibition of human CMV DNA synthesis in CMV-infected HEL cells.
    		[PMID: 7752205]
    HEL IC50
    0.5 μg/mL
    Compound: ganciclovir
    Anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells
    Anti CMV (Cytomegalovirus- virus) activity against AD-169 strain in HEL cells
    		[PMID: 9836626]
    HEL IC50
    0.5 μg/mL
    Compound: ganciclovir
    Anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells
    Anti CMV (Cytomegalovirus- virus) activity against Davis strain in HEL cells
    		[PMID: 9836626]
    HEL IC50
    0.9 μg/mL
    Compound: GCV
    Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.
    Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.
    		[PMID: 7877148]
    HEL IC50
    1 μM
    Compound: DHPG
    The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain
    The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain
    		[PMID: 10411487]
    HEL IC50
    1.2 μg/mL
    Compound: Ganciclovir
    Antiviral activity was measured against cytomegalovirus (CMV) AD-169 strain in human embryonic lung (HEL) cells
    Antiviral activity was measured against cytomegalovirus (CMV) AD-169 strain in human embryonic lung (HEL) cells
    		10.1016/S0960-894X(97)00149-2
    HEL IC50
    1.3 μg/mL
    Compound: Ganciclovir
    Antiviral activity was measured against cytomegalovirus (CMV) Davis strain in human embryonic lung (HEL) cells
    Antiviral activity was measured against cytomegalovirus (CMV) Davis strain in human embryonic lung (HEL) cells
    		10.1016/S0960-894X(97)00149-2
    HEL IC50
    1.5 μg/mL
    Compound: 11) 2 (Ganciclovir GCV)
    Antiviral activity against Cytomegalovirus (Davis strain) to reduce plaque formation in human embryonic lung (HEL) cells
    Antiviral activity against Cytomegalovirus (Davis strain) to reduce plaque formation in human embryonic lung (HEL) cells
    		10.1016/S0960-894X(01)80538-2
    HEL IC50
    2.7 μg/mL
    Compound: Ganciclovir
    Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Davis using HEL cell line
    Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Davis using HEL cell line
    		[PMID: 15745823]
    HEL IC50
    2.9 μg/mL
    Compound: GCV
    Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.
    Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.
    		[PMID: 7877148]
    HEL IC50
    2 μg/mL
    Compound: 11) 2 (Ganciclovir GCV)
    Antiviral activity against Cytomegalovirus (AD-169 strain) to reduce plaque formation in human embryonic lung (HEL) cells
    Antiviral activity against Cytomegalovirus (AD-169 strain) to reduce plaque formation in human embryonic lung (HEL) cells
    		10.1016/S0960-894X(01)80538-2
    HEL IC50
    5 μM
    Compound: DHPG
    The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain
    The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain
    		[PMID: 10411487]
    HEL IC50
    6.2 μg/mL
    Compound: GCV
    Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.
    Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.
    		[PMID: 7877148]
    HEL IC50
    7 μM
    Compound: ganciclovir
    Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR.
    Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR.
    		[PMID: 7752205]
    HEL IC50
    > 50 μM
    Compound: DHPG
    Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells
    Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology in human embryonic lung cells
    		[PMID: 10411487]
    HEL IC50
    > 50 μM
    Compound: DHPG
    The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%
    The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%
    		[PMID: 10411487]
    HEL 299 CC50
    > 100 μM
    Compound: 1b
    Cytotoxicity against human HEL299 cells after 3 days by MTT assay
    Cytotoxicity against human HEL299 cells after 3 days by MTT assay
    		[PMID: 26460883]
    HEL 299 CC50
    > 100 μM
    Compound: ganciclovir
    In vitro cytotoxicity of the compound (Concentration required to reduce OD value by 50%) in human embryonic lung fibroblast(HEL 299) cells determined by MTT assay.
    In vitro cytotoxicity of the compound (Concentration required to reduce OD value by 50%) in human embryonic lung fibroblast(HEL 299) cells determined by MTT assay.
    		[PMID: 9925738]
    HEL 299 CC50
    > 10 μg/mL
    Compound: GCV
    Cytotoxic concentration of compound was tested against HEL299(human embryonic lung fibroblast) cells using cytotoxic assay
    Cytotoxic concentration of compound was tested against HEL299(human embryonic lung fibroblast) cells using cytotoxic assay
    		[PMID: 11262090]
    HEL 299 CC50
    > 333 μM
    Compound: GCV, Ganciclovir
    Cytotoxicity against HEL299 cells infected with human cytomegalovirus after 7 days by alamar blue assay
    Cytotoxicity against HEL299 cells infected with human cytomegalovirus after 7 days by alamar blue assay
    		[PMID: 20047911]
    HEL 299 CC50
    > 400 μg/mL
    Compound: ganciclovir
    Compound was tested for its cytotoxicity against human embryonic lung fibroblast cells (HEL 299) by MTT dye reduction assay
    Compound was tested for its cytotoxicity against human embryonic lung fibroblast cells (HEL 299) by MTT dye reduction assay
    		10.1016/S0960-894X(00)80078-5
    HEL 299 CC50
    > 50 μM
    Compound: GCV
    Cytotoxicity against human HEL 299 cells assessed as cell death incubated for 168 hrs by MTS-based tetrazolium reduction assay
    Cytotoxicity against human HEL 299 cells assessed as cell death incubated for 168 hrs by MTS-based tetrazolium reduction assay
    		[PMID: 34147908]
    HEL 299 EC50
    0.63 μM
    Compound: ganciclovir
    In vitro antiviral (HCMV-AD169) activity of the compound (Concentration required to reduce 50% of the plaques) determined by plaque reduction assay.
    In vitro antiviral (HCMV-AD169) activity of the compound (Concentration required to reduce 50% of the plaques) determined by plaque reduction assay.
    		[PMID: 9925738]
    HEL 299 EC50
    2.39 μM
    Compound: GCV, Ganciclovir
    Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay
    Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay
    		[PMID: 20047911]
    HEp-2 EC50
    26.7 μg/mL
    Compound: gancyclovir
    Antiviral activity against VZV 3CV-1 infected in human Hep2 cells after 3 days by plaque neutralization assay
    Antiviral activity against VZV 3CV-1 infected in human Hep2 cells after 3 days by plaque neutralization assay
    		[PMID: 9599250]
    HEp-2 EC50
    5 μg/mL
    Compound: gancyclovir
    Antiviral activity against mCMV RM461 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days
    Antiviral activity against mCMV RM461 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days
    		[PMID: 9599250]
    HEp-2 IC50
    840 μg/mL
    Compound: gancyclovir
    Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days
    Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days
    		[PMID: 9599250]
    HEp-2 IC50
    > 100 μg/mL
    Compound: gancyclovir
    Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days
    Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days
    		[PMID: 9599250]
    HFF CC50
    550 μM
    Compound: GCV
    Cytotoxicity against human foreskin fibroblast after 5 days by MTT assay
    Cytotoxicity against human foreskin fibroblast after 5 days by MTT assay
    		[PMID: 19015358]
    HFF CC50
    550 μM
    Compound: GCV
    Cytotoxicity against human HFF by MTT assay
    Cytotoxicity against human HFF by MTT assay
    		[PMID: 20194695]
    HFF CC50
    > 100 μM
    Compound: 10
    Cytotoxicity against HFF cells by neutral red uptake assay
    Cytotoxicity against HFF cells by neutral red uptake assay
    		[PMID: 19397271]
    HFF CC50
    > 100 μM
    Compound: 10
    Cytotoxicity against HFF cells by plaque reduction assay
    Cytotoxicity against HFF cells by plaque reduction assay
    		[PMID: 19397271]
    HFF CC50
    > 100 μM
    Compound: 14
    Cytotoxicity against HFF cells
    Cytotoxicity against HFF cells
    		[PMID: 18082410]
    HFF CC50
    > 100 μM
    Compound: GCV
    Cytotoxicity against human HFF cells infected with Human cytomegalovirus AD169 assessed as viable cells by neutral red uptake assay
    Cytotoxicity against human HFF cells infected with Human cytomegalovirus AD169 assessed as viable cells by neutral red uptake assay
    		[PMID: 21376429]
    HFF CC50
    > 100 μM
    Compound: Ganciclovir
    In vitro cytotoxic concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line
    In vitro cytotoxic concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line
    		[PMID: 14736238]
    HFF CC50
    > 100 μM
    Compound: Ganciclovir
    Cytotoxic concentration against town strain of human cytomegalovirus infected HFF cells of human (visual cytotoxicity)
    Cytotoxic concentration against town strain of human cytomegalovirus infected HFF cells of human (visual cytotoxicity)
    		[PMID: 15634003]
    HFF CC50
    > 100 μM
    Compound: Ganciclovir
    Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay
    Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay
    		[PMID: 18595689]
    HFF CC50
    > 100 μM
    Compound: Ganciclovir
    Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay
    Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay
    		[PMID: 20403696]
    HFF CC50
    > 100 μM
    Compound: ganciclovir
    Cytotoxicity against HFF cells by visual cytotoxicity
    Cytotoxicity against HFF cells by visual cytotoxicity
    		[PMID: 15615545]
    HFF CC50
    > 100 μM
    Compound: ganciclovir
    Toxicity on uninfected human foreskin fibroblast cells determined in microscopic evaluation and quantitative neutral red dye uptake assay
    Toxicity on uninfected human foreskin fibroblast cells determined in microscopic evaluation and quantitative neutral red dye uptake assay
    		[PMID: 16134946]
    HFF CC50
    > 100 μM
    Compound: ganciclovir
    Cytotoxicity against HFF cell by neutral red uptake assay
    Cytotoxicity against HFF cell by neutral red uptake assay
    		[PMID: 17004726]
    HFF CC50
    > 100 μM
    Compound: ganciclovir
    Cytotoxicity against HFF cells by alamar blue assay
    Cytotoxicity against HFF cells by alamar blue assay
    		[PMID: 17329103]
    HFF CC50
    > 100 μM
    Compound: ganciclovir
    Cytotoxicity against HFF cells after 3 days
    Cytotoxicity against HFF cells after 3 days
    		[PMID: 17434304]
    HFF CC50
    > 100 μM
    Compound: ganciclovir
    Cytotoxicity against HFF
    Cytotoxicity against HFF
    		[PMID: 26260336]
    HFF CC50
    > 150 μM
    Compound: Ganciclovir
    Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 14 days by cell titer glo assay
    Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 14 days by cell titer glo assay
    		[PMID: 34124679]
    HFF CC50
    > 150 μM
    Compound: Ganciclovir
    Cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay
    Cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay
    		[PMID: 35754374]
    HFF CC50
    > 200 μM
    Compound: GCV
    Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs or 10 days by MTT assay
    Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs or 10 days by MTT assay
    		[PMID: 32191456]
    HFF CC50
    > 300 μM
    Compound: GCV
    Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining
    Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining
    		[PMID: 22607883]
    HFF CC50
    > 392 μM
    Compound: Ganciclovir
    In vitro cytotoxic concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line
    In vitro cytotoxic concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line
    		[PMID: 14736238]
    HFF CC50
    > 392 μM
    Compound: Ganciclovir
    Cytotoxic concentration against AD169 strain of human cytomegalovirus infected HFF cells of human (by neutral red uptake)
    Cytotoxic concentration against AD169 strain of human cytomegalovirus infected HFF cells of human (by neutral red uptake)
    		[PMID: 15634003]
    HFF CC50
    > 392 μM
    Compound: ganciclovir
    Cytotoxicity against HFF cells by neutral red uptake assay
    Cytotoxicity against HFF cells by neutral red uptake assay
    		[PMID: 15615545]
    HFF CC50
    > 50 μM
    Compound: 1; GCV
    Cytotoxicity against HFF cells assessed as cell viability incubated for 168 hrs by MTS-based Cell Titer assay
    Cytotoxicity against HFF cells assessed as cell viability incubated for 168 hrs by MTS-based Cell Titer assay
    		[PMID: 35377638]
    HFF EC50
    0.04 μM
    Compound: GCV
    Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay
    Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay
    		[PMID: 21376429]
    HFF EC50
    0.15 μM
    Compound: ganciclovir
    Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay
    Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay
    		[PMID: 17004726]
    HFF EC50
    0.5 μM
    Compound: ganciclovir
    Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells
    Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells
    		[PMID: 8394933]
    HFF EC50
    1.1 μM
    Compound: GCV
    Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    1.8 μM
    Compound: ganciclovir
    Inhibition of HCMV towne replication in HFF cells by plaque reduction assay
    Inhibition of HCMV towne replication in HFF cells by plaque reduction assay
    		[PMID: 17004726]
    HFF EC50
    2.1 μM
    Compound: ganciclovir
    Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay
    Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay
    		[PMID: 15615545]
    HFF EC50
    2.2 μM
    Compound: ganciclovir
    Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay
    Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay
    		[PMID: 15615545]
    HFF EC50
    2.3 μM
    Compound: Ganciclovir
    In vitro effective concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line
    In vitro effective concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line
    		[PMID: 14736238]
    HFF EC50
    2.5 μM
    Compound: 14
    Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay
    Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay
    		[PMID: 18082410]
    HFF EC50
    2.6 μM
    Compound: GCV
    Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    2.7 μM
    Compound: GCV
    Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    3.5 μM
    Compound: GCV
    Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    3.9 μM
    Compound: GCV
    Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    4.1 μM
    Compound: Ganciclovir
    In vitro effective concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line
    In vitro effective concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line
    		[PMID: 14736238]
    HFF EC50
    6.1 μM
    Compound: GCV
    Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    6.6 μM
    Compound: GCV
    Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF EC50
    8.4 μM
    Compound: GCV
    Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
    Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay
    		[PMID: 17709468]
    HFF IC50
    0.14 μM
    Compound: GCV
    Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay
    Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay
    		[PMID: 21812420]
    HFF IC50
    0.6 μM
    Compound: Ganciclovir
    Antiviral activity in a cell-based plaque reduction assay, using an HFF cell line and the Davis strain of HCMV
    Antiviral activity in a cell-based plaque reduction assay, using an HFF cell line and the Davis strain of HCMV
    		[PMID: 10999475]
    HFF IC50
    0.8 μM
    Compound: ganciclovir
    Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
    Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
    		[PMID: 16134946]
    HFF IC50
    0.8 μM
    Compound: ganciclovir
    Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
    Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
    		[PMID: 16134946]
    HFF IC50
    1 μM
    Compound: ganciclovir
    Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay
    Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay
    		[PMID: 17329103]
    HFF IC50
    1.2 μM
    Compound: GCV (table-1)
    Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay
    Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay
    		[PMID: 15509176]
    HFF IC50
    1.2 μM
    Compound: GCV (table-1)
    Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay
    Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay
    		[PMID: 15509176]
    HFF IC50
    1.2 μM
    Compound: GCV (table-1)
    Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay
    Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay
    		[PMID: 15509176]
    HFF IC50
    1.3 μM
    Compound: GCV
    Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay
    Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay
    		[PMID: 17043128]
    HFF IC50
    1.3 μM
    Compound: Ganciclovir
    Inhibition of HCMV DNA polymerase infected in HFF cells
    Inhibition of HCMV DNA polymerase infected in HFF cells
    		[PMID: 20403696]
    HFF IC50
    1.3 μM
    Compound: ganciclovir
    Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO
    Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO
    		[PMID: 16134946]
    HFF IC50
    1.4 μM
    Compound: GCV
    Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay
    Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay
    		[PMID: 17043128]
    HFF IC50
    1.4 μM
    Compound: GCV
    Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay
    Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay
    		[PMID: 17043128]
    HFF IC50
    1.9 μM
    Compound: GCV
    Antiviral activity against Human CMV AD169 in HFF cells by PRA
    Antiviral activity against Human CMV AD169 in HFF cells by PRA
    		[PMID: 17043128]
    HFF IC50
    10 μM
    Compound: GCV
    Antiviral activity against Human CMV T2293 in HFF cells by PRA
    Antiviral activity against Human CMV T2293 in HFF cells by PRA
    		[PMID: 17043128]
    HFF IC50
    12.4 μM
    Compound: GCV
    Antiviral activity against Human CMV T2311 in HFF cells by PRA
    Antiviral activity against Human CMV T2311 in HFF cells by PRA
    		[PMID: 17043128]
    HFF IC50
    1300 nM
    Compound: Ganciclovir
    Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay
    Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay
    		[PMID: 20167488]
    HFF IC50
    1300 nM
    Compound: ganciclovir
    Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay
    Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay
    		[PMID: 17434304]
    HFF IC50
    16.4 μM
    Compound: GCV
    Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay
    Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay
    		[PMID: 19010684]
    HFF IC50
    2.1 μM
    Compound: GCV
    Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay
    Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay
    		[PMID: 22607883]
    HFF IC50
    2.5 μM
    Compound: GCV (table-1)
    Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay
    Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay
    		[PMID: 15509176]
    HFF IC50
    2.6 μM
    Compound: Ganciclovir
    Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay
    Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay
    		[PMID: 9438017]
    HFF IC50
    3 μM
    Compound: Ganciclovir
    Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days
    Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days
    		[PMID: 21641218]
    HFF IC50
    3 μM
    Compound: ganciclovir
    Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay
    Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay
    		[PMID: 17161946]
    HFF IC50
    3.22 μM
    Compound: GCV
    Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay
    Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay
    		[PMID: 19010684]
    HFF IC50
    30.2 μM
    Compound: GCV
    Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay
    Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay
    		[PMID: 17043128]
    HFF IC50
    4.1 μM
    Compound: 1, Gancyclovir
    Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells
    Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells
    		[PMID: 10882374]
    HFF IC50
    4.1 μM
    Compound: GCV
    Antiviral activity against Human CMV T2291 in HFF cells by PRA
    Antiviral activity against Human CMV T2291 in HFF cells by PRA
    		[PMID: 17043128]
    HFF IC50
    4.4 μg/mL
    Compound: DHPG
    Anti HCMV(human cytomegalovirus) activity in HFF cell line Hs 68 infected with AD619 strain of HCMV(plaque reduction assay).
    Anti HCMV(human cytomegalovirus) activity in HFF cell line Hs 68 infected with AD619 strain of HCMV(plaque reduction assay).
    		[PMID: 7562929]
    HFF IC50
    4.5 μM
    Compound: 1, Gancyclovir
    Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells
    Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells
    		[PMID: 10882374]
    HFF IC50
    5.6 μM
    Compound: GCV
    Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay
    Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay
    		[PMID: 17043128]
    HFF IC50
    52 μg/mL
    Compound: DHPG
    Anti HCMV(human cytomegalovirus) activity in MRC-5 cells infected with DHPG-resistant D16 strain of HCMV(plaque reduction assay).
    Anti HCMV(human cytomegalovirus) activity in MRC-5 cells infected with DHPG-resistant D16 strain of HCMV(plaque reduction assay).
    		[PMID: 7562929]
    HFF IC50
    7.1 μM
    Compound: GCV
    Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay
    Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay
    		[PMID: 17043128]
    HFF IC50
    7.4 μM
    Compound: 1
    In vitro antiviral activity against HCMV (Towne strain) in HFF (human fibroblast) cells.
    In vitro antiviral activity against HCMV (Towne strain) in HFF (human fibroblast) cells.
    		[PMID: 9057865]
    HFF IC50
    7.4 μM
    Compound: 1, Gancyclovir
    Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells
    Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells
    		[PMID: 10882374]
    HFF IC50
    7.4 μM
    Compound: GCV (ganciclovir) (table-1)
    Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay
    Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay
    		[PMID: 15509174]
    HFF IC50
    7.4 μM
    Compound: GCV (ganciclovir) (table-1)
    Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay
    Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay
    		[PMID: 15509175]
    HFF IC50
    7.4 μM
    Compound: GCV (table-1)
    Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay
    Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay
    		[PMID: 15509176]
    HFF IC50
    7.4 μM
    Compound: Ganciclovir
    Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells
    Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells
    		[PMID: 10882370]
    HFF IC50
    7.4 μM
    Compound: Ganciclovir
    Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells
    Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells
    		[PMID: 10882372]
    HFF IC50
    7.4 μM
    Compound: Ganciclovir
    Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells
    Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells
    		[PMID: 10882375]
    HFF IC50
    7.4 μM
    Compound: Ganciclovir
    Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay
    Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay
    		[PMID: 9438017]
    HFF IC50
    7.7 μM
    Compound: Ganciclovir (DHPG)
    Antiviral activity was determined by the HCMV plaque assay using HFF cells
    Antiviral activity was determined by the HCMV plaque assay using HFF cells
    		[PMID: 9057866]
    HFF IC50
    8.4 μM
    Compound: Ganciclovir
    In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay.
    In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay.
    		10.1016/S0960-894X(00)80470-9
    HFF IC50
    > 100 μM
    Compound: 1
    Visual cytotoxicity was scored on Human foreskin fibroblasts (HFF cells) at the time of plaque enumeration.
    Visual cytotoxicity was scored on Human foreskin fibroblasts (HFF cells) at the time of plaque enumeration.
    		[PMID: 9057865]
    HFF IC50
    > 100 μM
    Compound: 1, Gancyclovir
    Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration
    Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration
    		[PMID: 10882374]
    HFF IC50
    > 100 μM
    Compound: DHPG
    Cytotoxicity against human foreskin fibroblasts (HFF) cells
    Cytotoxicity against human foreskin fibroblasts (HFF) cells
    		10.1016/S0960-894X(00)80628-9
    HFF IC50
    > 100 μM
    Compound: GCV
    Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination
    Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination
    		[PMID: 15509173]
    HFF IC50
    > 100 μM
    Compound: GCV
    Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay
    Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay
    		[PMID: 21812420]
    HFF IC50
    > 100 μM
    Compound: GCV (ganciclovir) (table-1)
    Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells
    Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells
    		[PMID: 15509174]
    HFF IC50
    > 100 μM
    Compound: GCV (ganciclovir) (table-1)
    Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells
    Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells
    		[PMID: 15509175]
    HFF IC50
    > 100 μM
    Compound: GCV (table-1)
    Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells
    Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells
    		[PMID: 15509176]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir
    Visual cytotoxicity against stationary human foreskin fibroblasts (HFF) cells at the time of HCMV plaque enumeration
    Visual cytotoxicity against stationary human foreskin fibroblasts (HFF) cells at the time of HCMV plaque enumeration
    		[PMID: 10882370]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir
    Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration
    Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration
    		[PMID: 10882372]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir
    Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells
    Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells
    		[PMID: 10882375]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir
    Tested for cytotoxic activity against human foreskin fibroblasts (HFF) cells.
    Tested for cytotoxic activity against human foreskin fibroblasts (HFF) cells.
    		[PMID: 2163453]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir
    Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells).
    Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells).
    		[PMID: 2175356]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir
    Cytotoxicity was evaluated against the Human diploid cells (HFF)
    Cytotoxicity was evaluated against the Human diploid cells (HFF)
    		[PMID: 2913300]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir
    Compound was evaluated for the visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration
    Compound was evaluated for the visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration
    		[PMID: 7562945]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir
    Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration
    Visual cytotoxicity scored on HFF cells at time of HCMV plaque enumeration
    		[PMID: 7562946]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir
    Visual cytotoxicity scored on HFF cells at the time of HCMV plaque enumeration.
    Visual cytotoxicity scored on HFF cells at the time of HCMV plaque enumeration.
    		[PMID: 7562947]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir
    Visual cytotoxicity of compound on HFF cells at time of HCMV plaque enumeration
    Visual cytotoxicity of compound on HFF cells at time of HCMV plaque enumeration
    		[PMID: 8632412]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir
    Cytotoxicity for the compound was determined in uninfected stationary human foreskin fibroblasts (HFF) cells.
    Cytotoxicity for the compound was determined in uninfected stationary human foreskin fibroblasts (HFF) cells.
    		[PMID: 9548814]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir
    Compound was evaluated for the cytotoxicity scored on HFF cells at time of HCMV plaque enumeration.
    Compound was evaluated for the cytotoxicity scored on HFF cells at time of HCMV plaque enumeration.
    		[PMID: 9575044]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir (DHPG)
    Cytotoxicity against uninfected human foreskin fibroblast(HFF cells)
    Cytotoxicity against uninfected human foreskin fibroblast(HFF cells)
    		[PMID: 2846837]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir (DHPG)
    Cytotoxicity in HFF cells was estimated by the visual scoring of cells affected by virus infection in the plaque reduction assay (data of single experiment)
    Cytotoxicity in HFF cells was estimated by the visual scoring of cells affected by virus infection in the plaque reduction assay (data of single experiment)
    		[PMID: 9057866]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir (DHPG)
    Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration
    Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration
    		[PMID: 9057867]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir (GCV)
    Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection.
    Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection.
    		[PMID: 8784444]
    HFF IC50
    > 100 μM
    Compound: Ganciclovir(DHPG)
    Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration
    Visual cytotoxicity was scored on HFF cells at time of HCMV plaque enumeration
    		[PMID: 9057868]
    HFF IC50
    > 100 μM
    Compound: ganciclovir
    The compound was tested for cytotoxicity against human foreskin fibroblast cell
    The compound was tested for cytotoxicity against human foreskin fibroblast cell
    		[PMID: 2840500]
    HFF IC50
    > 100 μM
    Compound: ganciclovir
    Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration
    Tested for the visual cytotoxicity on HFF cells at the time of human cytomegalovirus (HCMV) plaque enumeration
    		[PMID: 8071942]
    HFF IC50
    > 100 μM
    Compound: ganciclovir
    Tested for cytotoxicity in human foreskin fibroblasts at time of HCMV plaque enumeration
    Tested for cytotoxicity in human foreskin fibroblasts at time of HCMV plaque enumeration
    		[PMID: 8254613]
    HFF IC50
    > 100 μM
    Compound: ganciclovir
    Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay.
    Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay.
    		[PMID: 8784445]
    HFF IC50
    > 100 μM
    Compound: ganciclovir (DHPG)
    Compound was evaluated for cytotoxic activity against HFF cells
    Compound was evaluated for cytotoxic activity against HFF cells
    		[PMID: 2163454]
    HFF IC50
    > 100 μM
    Compound: gcv
    Cytotoxicity against HFF cells
    Cytotoxicity against HFF cells
    		[PMID: 16814545]
    HS27 CC50
    > 333 μM
    Compound: GCV, Ganciclovir
    Cytotoxicity against human HS27 cells infected with human cytomegalovirus after 7 days by alamar blue assay
    Cytotoxicity against human HS27 cells infected with human cytomegalovirus after 7 days by alamar blue assay
    		[PMID: 20047911]
    HS27 EC50
    0.32 μM
    Compound: GCV, Ganciclovir
    Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay
    Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay
    		[PMID: 20047911]
    HSV-2 ED50
    3 μg/mL
    Compound: 2a(GCV)
    Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures)
    Antiviral activity against HSV-2 cell line (concentration required to prevent viral cytopathic effect in half of primary rabbit kidney cell cultures)
    		[PMID: 2848125]
    HeLa CC50
    190 μg/mL
    Compound: Ganciclovir
    Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as reduction in cell growth
    Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as reduction in cell growth
    		[PMID: 19324473]
    HeLa CC50
    221.8 μM
    Compound: Ganciclovir
    Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay
    Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay
    		[PMID: 22459876]
    HeLa CC50
    > 50 μg/mL
    Compound: Ganciclovir
    Cytotoxic activity was measured in human embryonic lung cells (HeLa)
    Cytotoxic activity was measured in human embryonic lung cells (HeLa)
    		10.1016/S0960-894X(97)00149-2
    HeLa CC50
    > 50 μg/mL
    Compound: Ganciclovir
    Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as change in cell morphology
    Cytotoxicity against Varicella Zoster Virus infected human HeLa cells assessed as change in cell morphology
    		[PMID: 19324473]
    HeLa EC50
    > 100 μM
    Compound: Gancyclovir, DHPG
    Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines
    Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines
    		[PMID: 11495586]
    Hepatocyte EC50
    1.5 μg/mL
    Compound: GCV, Ganciclovir
    Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures
    Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures
    		[PMID: 11985471]
    Hs68 CC50
    12.5 μg/mL
    Compound: GCV
    Cytotoxic activity in Hs 68 cell line by inhibition of cell proliferation
    Cytotoxic activity in Hs 68 cell line by inhibition of cell proliferation
    		[PMID: 10888336]
    Hs68 CC50
    12.5 μg/mL
    Compound: ganciclovir
    Cytotoxicity in the Hs 68 cell line
    Cytotoxicity in the Hs 68 cell line
    		[PMID: 10447945]
    Jurkat CC50
    > 100 μM
    Compound: ganciclovir
    Cytotoxicity against human Jurkat cells by alamar blue assay
    Cytotoxicity against human Jurkat cells by alamar blue assay
    		[PMID: 17329103]
    Jurkat IC50
    > 100 μM
    Compound: gcv
    Cytotoxicity against human Jurkat cells
    Cytotoxicity against human Jurkat cells
    		[PMID: 16814545]
    KB IC50
    1000 μM
    Compound: Ganciclovir
    Tested for cytotoxic activity against human neoplastic cell line(KB cells).
    Tested for cytotoxic activity against human neoplastic cell line(KB cells).
    		[PMID: 2163453]
    KB IC50
    1000 μM
    Compound: Ganciclovir
    Cytotoxicity was evaluated in Human neoplastic cell line (KB)
    Cytotoxicity was evaluated in Human neoplastic cell line (KB)
    		[PMID: 2913300]
    KB IC50
    1000 μM
    Compound: Ganciclovir (DHPG)
    Cytotoxicity against human neoplastic cell line (KB)
    Cytotoxicity against human neoplastic cell line (KB)
    		[PMID: 2500527]
    KB IC50
    1000 μM
    Compound: ganciclovir
    Average percent inhibition of DNA, RNA, and protein synthesis determined in KB cells
    Average percent inhibition of DNA, RNA, and protein synthesis determined in KB cells
    		[PMID: 2840500]
    KB IC50
    3.5 μM
    Compound: Ganciclovir (DHPG)
    Antiviral activity was estimated by HSV-1 ELISA method (data of single experiment)
    Antiviral activity was estimated by HSV-1 ELISA method (data of single experiment)
    		[PMID: 9057866]
    KB IC50
    > 100 μM
    Compound: 1
    In vitro inhibition of KB (human carcinoma) cell growth.
    In vitro inhibition of KB (human carcinoma) cell growth.
    		[PMID: 9057865]
    KB IC50
    > 100 μM
    Compound: 1, Gancyclovir
    Compound was tested for inhibition of KB cell growth in quadruplicate assay
    Compound was tested for inhibition of KB cell growth in quadruplicate assay
    		[PMID: 10882374]
    KB IC50
    > 100 μM
    Compound: GCV
    Concentration required to inhibit KB cell line growth was determined by crystal violet staining method
    Concentration required to inhibit KB cell line growth was determined by crystal violet staining method
    		[PMID: 15509173]
    KB IC50
    > 100 μM
    Compound: GCV (ganciclovir) (table-1)
    Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells
    Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells
    		[PMID: 15509174]
    KB IC50
    > 100 μM
    Compound: GCV (ganciclovir) (table-1)
    Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells
    Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells
    		[PMID: 15509175]
    KB IC50
    > 100 μM
    Compound: GCV (table-1)
    Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells
    Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells
    		[PMID: 15509176]
    KB IC50
    > 100 μM
    Compound: Ganciclovir
    Compound was tested for the inhibition of KB cell growth in quadruplicate wells
    Compound was tested for the inhibition of KB cell growth in quadruplicate wells
    		[PMID: 10882370]
    KB IC50
    > 100 μM
    Compound: Ganciclovir
    Inhibition of KB cell growth was determined.
    Inhibition of KB cell growth was determined.
    		[PMID: 10882372]
    KB IC50
    > 100 μM
    Compound: Ganciclovir
    Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB).
    Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB).
    		[PMID: 1310744]
    KB IC50
    > 100 μM
    Compound: Ganciclovir
    Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells).
    Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells).
    		[PMID: 2175356]
    KB IC50
    > 100 μM
    Compound: Ganciclovir
    Compound was evaluated for the inhibition of KB cell growth determined in quadruplicate assay
    Compound was evaluated for the inhibition of KB cell growth determined in quadruplicate assay
    		[PMID: 7562945]
    KB IC50
    > 100 μM
    Compound: Ganciclovir
    cell growth inhibition was determined in KB cells in quadruplicate assays
    cell growth inhibition was determined in KB cells in quadruplicate assays
    		[PMID: 7562946]
    KB IC50
    > 100 μM
    Compound: Ganciclovir
    In vitro inhibition of KB cell proliferation.
    In vitro inhibition of KB cell proliferation.
    		[PMID: 7562947]
    KB IC50
    > 100 μM
    Compound: Ganciclovir
    Inhibitory activity of compound against KB cell growth [>-indicates IC50/IC90 was not reached at the noted (highest) concentration tested]
    Inhibitory activity of compound against KB cell growth [>-indicates IC50/IC90 was not reached at the noted (highest) concentration tested]
    		[PMID: 8632412]
    KB IC50
    > 100 μM
    Compound: Ganciclovir
    Cytotoxicity for the compound was determined by the inhibition of the growing KB cells.
    Cytotoxicity for the compound was determined by the inhibition of the growing KB cells.
    		[PMID: 9548814]
    KB IC50
    > 100 μM
    Compound: Ganciclovir
    Compound was evaluated for the cytotoxicity by the inhibition of KB cell growth.
    Compound was evaluated for the cytotoxicity by the inhibition of KB cell growth.
    		[PMID: 9575044]
    KB IC50
    > 100 μM
    Compound: Ganciclovir (DHPG)
    Cytotoxicity in KB cells.
    Cytotoxicity in KB cells.
    		[PMID: 9057866]
    KB IC50
    > 100 μM
    Compound: Ganciclovir (DHPG)
    Inhibition of KB cell growth was determined
    Inhibition of KB cell growth was determined
    		[PMID: 9057867]
    KB IC50
    > 100 μM
    Compound: Ganciclovir(DHPG)
    Inhibition of KB cell growth was determined
    Inhibition of KB cell growth was determined
    		[PMID: 9057868]
    KB IC50
    > 100 μM
    Compound: ganciclovir
    Tested for the inhibition of KB cell growth
    Tested for the inhibition of KB cell growth
    		[PMID: 8254613]
    KB IC50
    > 100 μM
    Compound: ganciclovir
    Inhibitory activity against growth of KB cell.
    Inhibitory activity against growth of KB cell.
    		[PMID: 8784445]
    KB IC50
    > 320 μM
    Compound: Ganciclovir (GCV)
    Cytotoxicity (growth inhibition) against human epidermoid oral carcinoma KB cell line.
    Cytotoxicity (growth inhibition) against human epidermoid oral carcinoma KB cell line.
    		[PMID: 8784444]
    MEF CC50
    > 35 μM
    Compound: Ganciclovir
    In vitro cytotoxic concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line
    In vitro cytotoxic concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line
    		[PMID: 14736238]
    MEF CC50
    > 392 μM
    Compound: Ganciclovir
    Cytotoxic concentration against murine cytomegalovirus infected MEF cells
    Cytotoxic concentration against murine cytomegalovirus infected MEF cells
    		[PMID: 15634003]
    MEF EC50
    0.96 μM
    Compound: GCV
    Antiviral activity against Mouse Cytomegalovirus Smith (ATCC VR-1399) infected in mouse MEF cells assessed as reduction in plaque formation measured after 3 days by crystal violet staining based assay
    Antiviral activity against Mouse Cytomegalovirus Smith (ATCC VR-1399) infected in mouse MEF cells assessed as reduction in plaque formation measured after 3 days by crystal violet staining based assay
    		[PMID: 32191456]
    MEF EC50
    5 μM
    Compound: Ganciclovir
    In vitro effective concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line
    In vitro effective concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line
    		[PMID: 14736238]
    MEF IC50
    3.4 μM
    Compound: Ganciclovir
    Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay
    Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay
    		[PMID: 9438017]
    MRC5 CC50
    98 μM
    Compound: ganciclovir
    Concentration required to reduce MRC-5 cell growth by 50%
    Concentration required to reduce MRC-5 cell growth by 50%
    		[PMID: 10966740]
    MRC5 CC50
    > 100 μM
    Compound: 1
    Cytotoxicity against human MRC5 cells by CCK-8 assay
    Cytotoxicity against human MRC5 cells by CCK-8 assay
    		[PMID: 37037115]
    MRC5 CC50
    > 100 μg/mL
    Compound: Ganciclovir
    Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
    Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
    		[PMID: 9934471]
    MRC5 CC50
    > 333 μM
    Compound: GCV, Ganciclovir
    Cytotoxicity against human MRC5 cells infected with human cytomegalovirus after 7 days by alamar blue assay
    Cytotoxicity against human MRC5 cells infected with human cytomegalovirus after 7 days by alamar blue assay
    		[PMID: 20047911]
    MRC5 EC50
    1.65 μM
    Compound: GCV, Ganciclovir
    Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay
    Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay
    		[PMID: 20047911]
    MRC5 EC50
    9.4 μM
    Compound: ganciclovir
    Inhibitory activity of compound against human cytomegalovirus (HCMV) in MRC-5 cells.
    Inhibitory activity of compound against human cytomegalovirus (HCMV) in MRC-5 cells.
    		[PMID: 12723951]
    MRC5 ED50
    0.4 μg/mL
    Compound: 2' NDG
    In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; 0.4-1.6
    In vitro anti viral activity tested against HCMV(AD169) virus on MRC-5 cell monolayers; 0.4-1.6
    		[PMID: 2989523]
    MRC5 ED50
    1 μg/mL
    Compound: 2' NDG
    In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; 1-2
    In vitro anti viral activity tested against VZV(KMcC) virus on MRC-5 cell monolayers; 1-2
    		[PMID: 2989523]
    MRC5 IC50
    0.91 μM
    Compound: GCV
    Antiviral activity against HCMV in MRC5 cells by plaque reduction assay
    Antiviral activity against HCMV in MRC5 cells by plaque reduction assay
    		[PMID: 17239594]
    MRC5 IC50
    1.2 μg/mL
    Compound: Ganciclovir
    Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains P8 using MRC-5 cell line
    Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains P8 using MRC-5 cell line
    		[PMID: 15745823]
    MRC5 IC50
    1.4 μM
    Compound: GCV
    Inhibitory concentration against Davis strain of HCMV in MRC5 cells
    Inhibitory concentration against Davis strain of HCMV in MRC5 cells
    		[PMID: 11454465]
    MRC5 IC50
    1.5 μM
    Compound: GCV
    Inhibitory concentration against Towne strain of HCMV in MRC5 cells
    Inhibitory concentration against Towne strain of HCMV in MRC5 cells
    		[PMID: 11454465]
    MRC5 IC50
    1.6 μM
    Compound: GCV
    Inhibitory concentration against 2599R strain of HCMV in MRC5 cells
    Inhibitory concentration against 2599R strain of HCMV in MRC5 cells
    		[PMID: 11454465]
    MRC5 IC50
    1.7 μM
    Compound: Ganciclovir
    In vitro antiviral activity against Human cytomegalovirus (HCMV)strain AD169 in MRC-5 lung fibroblasts using a DNA-hybridization assay
    In vitro antiviral activity against Human cytomegalovirus (HCMV)strain AD169 in MRC-5 lung fibroblasts using a DNA-hybridization assay
    		[PMID: 8176714]
    MRC5 IC50
    2.1 μg/mL
    Compound: Ganciclovir
    Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
    Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.
    		[PMID: 9934471]
    MRC5 IC50
    2.2 μg/mL
    Compound: Ganciclovir
    Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Ad169 using MRC-5 cell line
    Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Ad169 using MRC-5 cell line
    		[PMID: 15745823]
    MRC5 IC50
    3 μM
    Compound: GCV
    Inhibitory concentration against AD169 strain of HCMV in MRC5 cells
    Inhibitory concentration against AD169 strain of HCMV in MRC5 cells
    		[PMID: 11454465]
    MRC5 IC50
    3.2 μg/mL
    Compound: DHPG
    Anti HCMV (human cytomegalovirus) activity in MRC-5 cells infected with AD619 strain of HCMV (plaque reduction assay).
    Anti HCMV (human cytomegalovirus) activity in MRC-5 cells infected with AD619 strain of HCMV (plaque reduction assay).
    		[PMID: 7562929]
    MRC5 IC50
    30.1 μM
    Compound: GCV
    Antiviral activity against Human CMV T2287 in MRC5 cells by PRA
    Antiviral activity against Human CMV T2287 in MRC5 cells by PRA
    		[PMID: 17043128]
    MRC5 IC50
    4 μM
    Compound: ganciclovir
    In vitro antiherpesvirus activity against MRC-5 cells infected with HCMV (AD-169 strain)
    In vitro antiherpesvirus activity against MRC-5 cells infected with HCMV (AD-169 strain)
    		[PMID: 1323678]
    MRC5 IC50
    4.9 μM
    Compound: GCV
    Antiviral activity against Human CMV Towne in MRC5 cells by PRA
    Antiviral activity against Human CMV Towne in MRC5 cells by PRA
    		[PMID: 17043128]
    MRC5 IC50
    5.4 μM
    Compound: GCV
    Antiviral activity against Human CMV T2296 in MRC5 cells by PRA
    Antiviral activity against Human CMV T2296 in MRC5 cells by PRA
    		[PMID: 17043128]
    MRC5 IC50
    5.9 μM
    Compound: ganciclovir
    Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells
    Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells
    		[PMID: 10966740]
    MRC5 IC50
    6.3 μM
    Compound: GCV
    Inhibitory concentration for anti-HCMV activity against AD-169 strain in MRC-5 cells
    Inhibitory concentration for anti-HCMV activity against AD-169 strain in MRC-5 cells
    		[PMID: 9836613]
    MRC5 IC50
    7.8 μg/mL
    Compound: Ganciclovir
    Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains D16(UL54 mutation) using MRC-5 cell line
    Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains D16(UL54 mutation) using MRC-5 cell line
    		[PMID: 15745823]
    MRC5 IC50
    8.7 μg/mL
    Compound: Ganciclovir
    Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains C8704(UL97 mutation) using MRC-5 cell line
    Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains C8704(UL97 mutation) using MRC-5 cell line
    		[PMID: 15745823]
    MRC5 IC50
    970 μM
    Compound: GCV
    Cytotoxicity against MRC5 cells
    Cytotoxicity against MRC5 cells
    		[PMID: 17239594]
    MRC5 IC50
    > 10 μM
    Compound: GCV
    Inhibitory concentration against Xba F strain of HCMV in MRC5 cells
    Inhibitory concentration against Xba F strain of HCMV in MRC5 cells
    		[PMID: 11454465]
    MT4 IC50
    > 50 μM
    Compound: 1
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by cell counting method
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by cell counting method
    		[PMID: 28829913]
    NHDF CC50
    > 333 μM
    Compound: GCV, Ganciclovir
    Cytotoxicity against NHDF infected with human cytomegalovirus after 7 days by alamar blue assay
    Cytotoxicity against NHDF infected with human cytomegalovirus after 7 days by alamar blue assay
    		[PMID: 20047911]
    NIH3T3 EC50
    5.7 μM
    Compound: GCV
    Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay
    Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay
    		[PMID: 18458124]
    Neoplastic cell line IC50
    > 100 μM
    Compound: ganciclovir (DHPG)
    Compound was evaluated for cytotoxic activity against KB cells
    Compound was evaluated for cytotoxic activity against KB cells
    		[PMID: 2163454]
    OST IC50
    0.0019 μM
    Compound: GCV
    Cytotoxicity against human OST TK- cells expressing HSV1 TK
    Cytotoxicity against human OST TK- cells expressing HSV1 TK
    		[PMID: 17181158]
    OST IC50
    0.018 μM
    Compound: GCV
    Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine
    Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine
    		[PMID: 17181158]
    OST IC50
    0.033 μM
    Compound: GCV
    Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine
    Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine
    		[PMID: 17181158]
    OST IC50
    0.041 μM
    Compound: GCV
    Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine
    Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine
    		[PMID: 17181158]
    OST IC50
    0.05 μM
    Compound: GCV
    Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
    Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
    		[PMID: 17181158]
    OST IC50
    0.081 μM
    Compound: GCV
    Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
    Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
    		[PMID: 17181158]
    OST IC50
    0.11 μM
    Compound: GCV
    Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
    Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine
    		[PMID: 17181158]
    Osteoclast-like IC50
    30 μM
    Compound: gcv
    Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage
    Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage
    		[PMID: 16814545]
    RG2 CC50
    377 μM
    Compound: GCV
    Cytotoxicity against RG2 cells after 72 hrs by MTT assay
    Cytotoxicity against RG2 cells after 72 hrs by MTT assay
    		[PMID: 18800764]
    Vero CC50
    666 μM
    Compound: GCV
    Cytotoxicity against african green monkey Vero cells after 2 days
    Cytotoxicity against african green monkey Vero cells after 2 days
    		[PMID: 17438061]
    Vero CC50
    > 100 μM
    Compound: ganciclovir
    Toxicity on uninfected African green monkey kidney cells determined in microscopic evaluation and quantitative neutral red dye uptake assay
    Toxicity on uninfected African green monkey kidney cells determined in microscopic evaluation and quantitative neutral red dye uptake assay
    		[PMID: 16134946]
    Vero EC50
    0.025 μM
    Compound: GCV
    Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of GFP expression after 72 hrs by GFP-based fluorescence microscopic analysis
    Antiviral activity against HSV-1 infected in African green monkey Vero cells assessed as inhibition of GFP expression after 72 hrs by GFP-based fluorescence microscopic analysis
    		[PMID: 31503476]
    Vero EC50
    0.04 μM
    Compound: GCV
    Antiviral activity against HSV 1 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay
    Antiviral activity against HSV 1 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay
    		[PMID: 32191456]
    Vero EC50
    0.23 μM
    Compound: Ganciclovir
    Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%
    Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%
    		[PMID: 11585457]
    Vero EC50
    0.58 μM
    Compound: GCV
    Antiviral activity against HSV 2 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay
    Antiviral activity against HSV 2 infected in African green monkey Vero cells assessed as reduction in plaque formation incubated for 36 hrs by crystal violet staining based assay
    		[PMID: 32191456]
    Vero EC50
    0.7 μM
    Compound: GCV
    Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    		[PMID: 17438061]
    Vero EC50
    0.9 μM
    Compound: 1b
    Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay
    Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay
    		[PMID: 26460883]
    Vero EC50
    1.4 μM
    Compound: 1b
    Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay
    Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay
    		[PMID: 26460883]
    Vero EC50
    11.1 μM
    Compound: 1b
    Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay
    Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay
    		[PMID: 26460883]
    Vero EC50
    14.5 μM
    Compound: GCV
    Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    		[PMID: 17438061]
    Vero EC50
    19.2 μM
    Compound: GCV
    Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    		[PMID: 17438061]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    19.3 μM
    Compound: GCV
    Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay
    Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay
    		[PMID: 19858259]
    Vero EC50
    2.14 μM
    Compound: 1b
    Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay
    Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay
    		[PMID: 26460883]
    Vero EC50
    23.5 μM
    Compound: GCV
    Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
    		[PMID: 17438061]
    Vero EC50
    > 50 μM
    Compound: ganciclovir
    Inhibition of HSV1 in Vero cells by plaque reduction assay
    Inhibition of HSV1 in Vero cells by plaque reduction assay
    		[PMID: 15615545]
    Vero EC50
    > 50 μM
    Compound: ganciclovir
    Inhibition of HSV2 in Vero cells by plaque reduction assay
    Inhibition of HSV2 in Vero cells by plaque reduction assay
    		[PMID: 15615545]
    Vero IC50
    0.1 μM
    Compound: 1 (BW-B759U, ganciclovir)
    Inhibition of growth of herpes simplex virus (HSV-1) by plaque reduction assay in vero cell line
    Inhibition of growth of herpes simplex virus (HSV-1) by plaque reduction assay in vero cell line
    		[PMID: 2826784]
    Vero IC50
    0.1 μM
    Compound: 1 (BW-B759U, ganciclovir)
    Inhibition of growth of herpes simplex virus (HSV-2) by plaque reduction assay in vero cell line
    Inhibition of growth of herpes simplex virus (HSV-2) by plaque reduction assay in vero cell line
    		[PMID: 2826784]
    Vero IC50
    1.22 μg/mL
    Compound: Ganciclovir
    Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line
    Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line
    		[PMID: 15745823]
    Vero IC50
    1.274 μg/mL
    Compound: Ganciclovir
    Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line
    Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line
    		[PMID: 15745823]
    Vero IC50
    2.8 μM
    Compound: 1 (BW-B759U, ganciclovir)
    Inhibition of growth of varicella zoster virus(VZV) by plaque reduction assay in vero cell line
    Inhibition of growth of varicella zoster virus(VZV) by plaque reduction assay in vero cell line
    		[PMID: 2826784]
    carcinoma cell line IC50
    > 100 μM
    Compound: Ganciclovir
    Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay.
    Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay.
    		[PMID: 10882375]
    In Vitro

    Ganciclovir (BW 759) is an acyclic deoxyguanosine analog structurally similar to acyclovir but with superior activity against CMV. The median Ganciclovir concentration required to inhibit viral replication by 50 percent is 2.15 μM versus 72 μM for acyclovir[4].
    The primary mechanism of Ganciclovir action against CMV is inhibition of the replication of viral DNA by ganciclovir-5'-triphosphate (ganciclovir-TP). This inhibition includes a selective and potent inhibition of the viral DNA polymerase. Ganciclovir is metabolized to the triphosphate form by primarily three cellular enzymes: a deoxyguanosine kinase induced by CMV-infected cells; guanylate kinase; and phosphoglycerate kinase[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ganciclovir Related Antibodies
    In Vivo

    Ganciclovir (BW 759) (50 mg/kg; i.p.; twice a day for five injections) significantly decreases white blood cells, red blood cells and platelets in newborn mice, and can diffuse into the brain and the perilymphatic space of the inner ear[3].
    Ganciclovir (1-80 mg/kg; i.h.; daily for 5 days) delays murine cytomegalovirus (MCMV)-induced wasting syndrome and mortality[6].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Non-inbred Oncins France 1 (OF1) mice and albino rats non-immunized for MCMV[3]
    Dosage: 50 mg/kg
    Administration: Intraperitoneal injection, twice a day for five injections (mice) or 3 days (adult rats) (Pharmacokinetic Study)
    Result: In adult rats, the intracochlear diffusion of Ganciclovir was shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of Ganciclovir showed a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but became undetectable by 2 h after injection.
    Significantly decreased white blood cells, red blood cells and platelets in newborn mice.
    Animal Model: Female SCID mice inoculated with MCMV[6]
    Dosage: 0, 1, 10, 80 and 160 mg/kg
    Administration: Subcutaneous injection, once daily for 5 days
    Result: Dose dependently delayed the wasting syndrome and mortality in a dose range up to 80 mg/kg per day, whereas a dose of 160 mg/kg per day induced reversible side-effects.
    Clinical Trial
    Molecular Weight

    255.23

    Formula

    C9H13N5O4
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C1NC(N)=NC2=C1N=CN2COC(CO)CO
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMSO : 60 mg/mL (235.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 1.67 mg/mL (6.54 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.9180 mL 19.5899 mL 39.1797 mL
    5 mM 0.7836 mL 3.9180 mL 7.8359 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.08 mg/mL (8.15 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.08 mg/mL (8.15 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 3.33 mg/mL (13.05 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.89%

    SDS (419 KB)

    COA (250 KB) HNMR (242 KB) RP-HPLC (262 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 3.9180 mL 19.5899 mL 39.1797 mL 97.9493 mL
    5 mM 0.7836 mL 3.9180 mL 7.8359 mL 19.5899 mL
    DMSO 10 mM 0.3918 mL 1.9590 mL 3.9180 mL 9.7949 mL
    15 mM 0.2612 mL 1.3060 mL 2.6120 mL 6.5300 mL
    20 mM 0.1959 mL 0.9795 mL 1.9590 mL 4.8975 mL
    25 mM 0.1567 mL 0.7836 mL 1.5672 mL 3.9180 mL
    30 mM 0.1306 mL 0.6530 mL 1.3060 mL 3.2650 mL
    40 mM 0.0979 mL 0.4897 mL 0.9795 mL 2.4487 mL
    50 mM 0.0784 mL 0.3918 mL 0.7836 mL 1.9590 mL
    60 mM 0.0653 mL 0.3265 mL 0.6530 mL 1.6325 mL
    80 mM 0.0490 mL 0.2449 mL 0.4897 mL 1.2244 mL
    100 mM 0.0392 mL 0.1959 mL 0.3918 mL 0.9795 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Ganciclovir Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Ganciclovir82410-32-0BW 759 2'-Nor-2'-deoxyguanosineBW759BW-759CMVHSVAntibioticNucleoside Antimetabolite/AnalogCytomegalovirusHerpes simplex virusDNAviruseherpesgroupinfectionserotypepolymerasereplicationCNS penetrationorally activecytomegalovirusInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Ganciclovir
    Cat. No.:
    HY-13637
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (419 KB) Français - FR (419 KB) Deutsch - DE (419 KB) Norwegian - NO (419 KB) Español - ES (419 KB) Swedish - SV (419 KB) Italian - IT (419 KB) Korean - KR (419 KB) Portuguese - PT (419 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.